Nautilus Q4 operating expenses fall 23%, net loss narrows

Nautilus Biotechnology

26/02/2026 13:07

Overview

Proteome analysis platform's Q4 operating expenses decreased 23% yr/yr

Net loss for Q4 narrowed compared to the previous year

Company does not anticipate material revenue from Early Access Program in 2026

Outlook

Company expects operating expenses to rise 15-20% in 2026

Nautilus anticipates no material revenue from Early Access Program in 2026

Company believes cash reserves will fund operations through 2027

Result Drivers

TAU PROTEOFORMS - Progress in processing and analyzing Tau proteoform samples supported platform validation and scientific publications

COST MANAGEMENT - Decrease in operating expenses attributed to reduced salaries, benefits, and development costs

EARLY ACCESS PROGRAM - Launched Iterative Mapping Early Access Program with encouraging initial customer response

Company press release: ID:nGNX2lMQfg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.11
Q4 Net Income
-$13.78 mln
Q4 Operating Expenses
$15.42 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $2.50, about 13.5% below its February 25 closing price of $2.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)